Autopsy report · NCT00849316
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
Cause of deathFunding or business, also staffing, sites or logistics
“Due to company decision to focus resources on the finalisation of three ongoing studies in the region”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Conditions
- Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Chronic Kidney Disease
- Interventions
- insulin aspart
- Participants
- 0
Trials that died the same way
- Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®
“This study has been cancelled before initiation due to company's prioritisation decisions linked to resources restrictions.” - Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
“study stopped due to company strategic prioritization” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations” - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
“This study has been cancelled due to business reasons” - A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain
“Company decision after projects re-evaluation, taken before the study initiation.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.